Share Prices & Company Research

Market News

30 Jun 2020 | 18:34

Inovio Pharmaceuticals's Covid-19 vaccine triggers immune response

(Sharecast News) - Inovio Pharmaceuticals's experimental vaccine against the novel coronavirus was found to be safe in an early stage clinical trial and successfully induced an immune response in the majority of participants in the test. Despite the results of the trial, as of 1803 BST shares of Inovio were slumping by 17.51% to $26.14 after some analysts sounded a cautious note on the results.

"We'd like to see data on these measures separately and broken out by dose before drawing too many conclusions," Piper Sandler analyst, Christopher Raymond, said.

The vaccine achieved immune responses - measured in the form of binding antibodies and T-cells - in 34 of 36 healthy volunteers participating in the trial, with full data set to be published in a peer-reviewed medical journal later on.

Admittedly however, the stock's price had more than doubled over the preceding seven sessions.

And for the biotech outfit's boss, Joseph Kim, the trial had been a success, Reuters reported.

Kim reportedly also claimed that his company's vaccine was likely the safest vaccine from among the various platforms being used against Covid-19.

A mid-to-late stage trial to evaluate the efficacy of the vaccine in summer.

Earlier, America's main regulatory body, the Food&Drug Administration had said that for a coronavirus vaccine to be deemed effective it would have to be able to either protect from infection or lower the severity of symptoms in at least half of those innoculated with it.

Inovio's vaccine was one of 17 being developed as part of the Trump administration's 'Warp Speed' programme.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 10th July 2020
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.